AbbVie’s share price rises after FDA approves arthritis treatment by

© Reuters

By Sam Boughedda — Share AbbVie (NYSE :) The company’s arthritis drug rose 1.8% on Friday after being approved by the US Food and Drug Administration.

The drug, named Rinvoq, is approved for the treatment of adults with active psoriatic arthritis who have an inadequate or intolerant response to tumor necrosis factor (TNF) blockers.

AbbVie said the approval was supported by two Phase 3 clinical trials using drugs that were effective across multiple measurements of disease activity.

Rinvoq is said to improve joint pain, swelling, stiffness and fatigue. This will be the second approval after the approval of rheumatoid arthritis in 2019.

Michael Severino, Vice Chairman and President of AbbVie, said:

In response to the announcement, Piper Sandler analysts maintained a stock overvaluation and a $ 160 price target, but Limbock invested in being approved with a “better than expected” atopic dermatitis label. I told my house.

“The drug is now ready to take advantage of what was positive for most of the feedback from dermatologists’ surveys on this opportunity, with the seemingly benign warning language and dosing flexibility. I think it’s done, “explained the analyst.

Disclaimer: Fusion media We inform you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are provided by the market maker, not the exchange, so prices may not be accurate and may differ from actual market prices. In other words, price is an indicator and is not suitable for trading purposes. Therefore, Fusion Media is not responsible for any transactional losses that may occur as a result of using this data.

Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.

AbbVie’s share price rises after FDA approves arthritis treatment by

Source link AbbVie’s share price rises after FDA approves arthritis treatment by

Related Articles

Back to top button